Multimodality treatment of malignant glioma

doi:10.3760/cma.j.issn.1673-422X.2014.11.006

Abstract

Abstract: Malignant gliomas cells grow invasively with no clear boundary, and a complete resection surgery is very difficult, and the pathological type is not sensitive to radiotherapy and chemotherapy, so the overall treatment effect is not ideal, and this disease is very prone to local recurrence after treatment. The treatment of malignant glioma is mainly composed of surgical resection with postoperative radiotherapy and chemotherapy. Other new treatments include targeted therapy, immune therapy, gene therapy and so on.

Key words: Glioma, Combined modality therapy

DONG Fang, XUE Jin-Cai, WANG Xiao-Hu. Multimodality treatment of malignant glioma[J]. Journal of International Oncology, 2014, 41(11): 816-820.

References

［1］温林豹，陈刚．胶质瘤的治疗策略［J］. 中华神经外科疾病研究杂志， 2011, 10(4):382384．［2］ GilRobles S, Duffau H. Surgical management of World Health Organization Grade Ⅱ gliomas in eloquent areas: the necessity of preserving a margin around functional structures［J］. Neurosurg Focus, 2010, 28(2):E8. ［3］张锐，金华，吕中华，等. 胶质瘤手术及辅助技术的进展［J］. 现代肿瘤医学, 2014, 22(4):937941. ［4］黄维, 兰胜民, 曹建忠, 等. 高分级脑胶质瘤术后精确放疗预后影响因素分析［J］.中华肿瘤防治杂志, 2013, 20(18):14181421. ［5］王林, 傅先明. 脑胶质瘤的外科治疗进展［J］. 国际神经病学神经外科学杂志, 2011, 38(3):241244. ［6］桂学宝, 傅先明. 脑胶质瘤综合治疗进展［J］. 立体定向和功能性神经外科杂志, 2013, 26(4):250253. ［7］ Mezger U, Jendrewski C, Bartels M. Navigation in surgery［J］. Langenbecks Arch Surg, 2013, 398(4): 50114. ［8］于圣平, 孙健, 俞凯, 等. 多模态多维影像融合技术在脑胶质瘤手术中的应用［J］.中国现代神经疾病杂志, 2012, 12(6):669674. ［9］许志强. 脑胶质瘤的临床治疗进展［J］. 中国临床神经科学, 2010, 4（18）:431435. ［10］杭春华. 脑胶质瘤的治疗进展［J］. 中国微侵袭神经外科杂志, 2011, 16(9):429432. ［11］ Behbahaninia M, Martirosyan NL, Georges J, et al. Intraoperative fluorescent imaging of intracranial tumors: a review［J］. Clin Neurol Neurosurg, 2013, 115(5): 517528. ［12］ Eyüpoglu IY, Hore N, Savaskan NE, et al. Improving the extent of malignant glioma resection by dual intraoperative visualization approach ［J］. PLoS One, 2012, 7(9):e44885. ［13］ Idoate MA, Diez Valle R, Echeveste J, et al. Pathological characterization of the glioblastoma border as shown during surgery using 5aminolevulinic acidinduced fluorescence［J］.Neuropathology, 2011, 31(6):575582. ［14］ Valdés PA, Kim A, Brantsch M, et al. δaminolevulinic acidinduced protoporphyrin Ⅸ concentration correlates with histopathologic markers of malignancy in human gliomas:the need for quantitative fluorescence guided resection to identify regions of increasing malignancy［J］. Neuro Oncol, 2011, 13(8):846856．［15］ Pickles T, Goodman GB, Rheaume DE, et al. Pion radiation for high grade astrocytoma:results of a randomized study［J］. Int J Radiat Oncol Biol Phys, 1997, 37(3): 491497. ［16］李春田, 刘思杰, 殷增进, 等. 伽马刀治疗脑胶质瘤术后残留60例临床疗效观察［J］. 临床军医杂志, 2013, 41（10）:1095. ［17］ Ruge MI, Kickingereder P, Grau S, et al. Stereotactic iodine125 brachytherapy for the treatment of WHO grades II and III gliomas located in the central sulcus region［J］. Neuro Oncol, 2013, 15(12):17211731. ［18］肖勇, 刘健, 李玉明. 125I放射性粒子永久植入治疗脑胶质瘤的临床探讨［J］.中国临床神经外科杂志, 2010, 15（11）:676678. ［19］ Clarke J, Butowski N, Chang S. Recent advances in therapy for glioblastoma［J］. Arch Neurol, 2010, 67(3):279283.. ［20］ Bourne TD, Schiff D. Update on molecular findings,management and outcome in lowgrade gliomas［J］. Nat Rev Neurol, 2010, 6(12):695701. ［21］ Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase Ⅲ study: 5year analysis of the EORTCNCIC trial［J］. Lancet Oncol, 2009, 10(5):459466. ［22］ Grossman SA, Ye X, Lesser G, et al. Immunosuppression in patients with highgrade gliomas treated with radiation and temozolomide［J］. Clin Cancer Res, 2011, 17(16):54735480. ［23］汪洋. 高分级胶质瘤化疗治疗进展［J］. 上海医药， 2012, 33(23):1013. ［24］ Guiu S, Taillibert S, Chinot O, et al. Bevacizumab/irinotecan.An active treatment for recurrent high grade gliomas:preliminary results of an ANOCEF Multicenter Study［J］. Rev Neurol(Paris), 2008, 164(67):588594. ［25］ Yung WK, Albright RE, Olson J, et al. A phase Ⅱ study of temozolomide vs.procarbazine in patients with glioblastoma multiforme at first relapse［J］. Br J Cancer, 2000, 83(5):588593. ［26］ Kreisl TN, Kim L, Moore K, et al. Phase Ⅱ trial of singleagent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma［J］. J Clin Oncol, 2009, 27(5):740745. ［27］ Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma［J］.J Clin Oncol, 2009, 27(28):47334740. ［28］ Diaz Miqueli A, Rolff J, Lemm M, et al. Radiosensitisation of U87MG brain tumours by antiepidermal growth factor receptor monoclonal antibodies［J］. Br J Cancer, 2009, 100(6):950958. ［29］李文斌, 陈静, 赵艳杰，等. 尼妥珠单抗联合术后同步放化疗治疗华人恶性胶质瘤的Ⅰ期临床试验［J］. 中国肿瘤临床, 2013, 40(23):14551459. ［30］ Wheeler CJ, Black KL. Vaccines for glioblastoma and highgrade glioma［J］. Expert Rev Vaccines, 2011, 10(6):875886. ［31］冯英楠, 陈菲, 庄伟, 等. 中医药治疗胶质瘤的研究进展［J］. 北京中医药, 2014, 33(2):154157. ［32］杨利辉，石文建，赵喜庆. 鸦胆子油乳对SKMG4 胶质瘤细胞抑制作用研究［J］.中华神经外科疾病研究杂志, 2011, 10(1):3840. ［33］田刚, 雷宁, 王晓娟, 等. 姜黄素对抑制大鼠C6 胶质瘤生成及机制初步研究［J］.现代生物学进展, 2012, 12(4):635637.

[1]	Liu Pingping, He Xuefang, Zhang Yi, Yang Xu, Zhang Shanshan, Ji Yifei. Risk factors of postoperative recurrence in patients with primary brain glioma and prediction model construction [J]. Journal of International Oncology, 2024, 51(4): 193-197.
[2]	Tian Jinming, Yang Jijin. Research progress of locoregional interventional therapies combined with immune checkpoint inhibitors for intermediate-advanced hepatocellular carcinoma [J]. Journal of International Oncology, 2023, 50(10): 636-640.
[3]	Song Jia, Hu Qinyong. Application of TACE combined with molecular targeted therapy and immunotherapy in BCLC B/C hepatocellular carcinoma [J]. Journal of International Oncology, 2022, 49(9): 550-554.
[4]	Xiao Nan, Sun Pengfei. Research progress of oxidative stress in the sensitivity of chemoradiotherapy for gliomas [J]. Journal of International Oncology, 2022, 49(6): 357-361.
[5]	Zhang Rui, Feng Enzi, Ren Yanxin, Li Xiaojiang. Advances in non-operative treatment of advanced hypopharyngeal squamous cell carcinoma [J]. Journal of International Oncology, 2022, 49(4): 233-236.
[6]	Gao Min, Feng Jing, Wang Li, Zhong Hai, Wen Yuting, Wan Bing, Zhang Xiuwei. Application of microbiota in the early diagnosis and adjunctive treatment of lung cancer [J]. Journal of International Oncology, 2022, 49(4): 247-251.
[7]	Zhu Yishuo, Cui Yujie, Liu Qi, Li Jun, Fan Yuechao. Analysis of risk factors and prediction model establishment for early postoperative recurrence in glioma patients [J]. Journal of International Oncology, 2022, 49(2): 79-83.
[8]	Kong Chunyu, Sun Pengfei. SLC7A11 and glioma [J]. Journal of International Oncology, 2022, 49(10): 604-607.
[9]	Di Weihua, Zhao Xuemei. Research progress on the relationship between DNA damage repair genes and liver cancer [J]. Journal of International Oncology, 2022, 49(10): 635-638.
[10]	Guo Shihao, Ren Yeqing, Guo Geng. Molecular mechanism of vasculogenic mimicry in brain glioma [J]. Journal of International Oncology, 2021, 48(6): 362-365.
[11]	Wang Xianwei, Shi Meiyan, Wang Fengqin, Qi Fu, Wang Chaozhe, Zhou Fei. Roles of TSA upregulation miR-4298 targeting inhibition of PADI4 expression in inducing U251 cells apoptosis [J]. Journal of International Oncology, 2021, 48(4): 193-199.
[12]	Sun Yanqi, Ren Yeqing, Guo Geng. Mechanism of inhibitory effect of interferon and its related signal pathway on the invasion of glioma [J]. Journal of International Oncology, 2021, 48(3): 172-175.
[13]	Zhao Congxuan, Yu Tao. Mining and prediction of glioma-related genes [J]. Journal of International Oncology, 2020, 47(5): 293-296.
[14]	Zheng Xin, Chen Xiaopin. Relationship between HPV and oropharyngeal cancer in China [J]. Journal of International Oncology, 2020, 47(3): 164-168.
[15]	Nan Yang, Zhong Yue. New research advances of long non-coding RNA in glioma [J]. Journal of International Oncology, 2020, 47(2): 98-102.